stoxline Quote Chart Rank Option Currency Glossary
  
Caribou Biosciences, Inc. (CRBU)
5.12  0.06 (1.19%)    03-27 16:00
Open: 5.14
High: 5.175
Volume: 967,096
  
Pre. Close: 5.06
Low: 5.05
Market Cap: 462(M)
Technical analysis
2024-03-27 4:52:06 PM
Short term     
Mid term     
Targets 6-month :  8.23 1-year :  9.72
Resists First :  7.05 Second :  8.32
Pivot price 5.69
Supports First :  4.98 Second :  4.15
MAs MA(5) :  5.19 MA(20) :  6.16
MA(100) :  5.87 MA(250) :  5.44
MACD MACD :  -0.5 Signal :  -0.4
%K %D K(14,3) :  6 D(3) :  7.4
RSI RSI(14): 35.2
52-week High :  8.59 Low :  3.44
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CRBU ] has closed above bottom band by 32.9%. Bollinger Bands are 82.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.18 - 5.22 5.22 - 5.24
Low: 4.98 - 5.02 5.02 - 5.05
Close: 5.07 - 5.13 5.13 - 5.18
Company Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Headline News

Wed, 27 Mar 2024
Investors in Caribou Biosciences (NASDAQ:CRBU) from a year ago are still down 46%, even after 11% gain this past ... - Yahoo Movies UK

Mon, 25 Mar 2024
Caribou Biosciences (NASDAQ:CRBU) Trading 6.5% Higher - MarketBeat

Sat, 23 Mar 2024
Exchange Traded Concepts LLC Buys 6066 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World

Sat, 23 Mar 2024
Aura Biosciences (NASDAQ:AURA) & Caribou Biosciences (NASDAQ:CRBU) Head-To-Head Survey - Defense World

Thu, 21 Mar 2024
Q1 2024 Earnings Forecast for Caribou Biosciences, Inc. (NASDAQ:CRBU) Issued By HC Wainwright - MarketBeat

Thu, 14 Mar 2024
Caribou Biosciences (NASDAQ:CRBU): Recent Price Volatility May Offer Investors an Entry Point - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 90 (M)
Held by Insiders 6.848e+007 (%)
Held by Institutions 12.4 (%)
Shares Short 10,120 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.1253e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -296.1 %
Operating Margin -1 %
Return on Assets (ttm) 52.3 %
Return on Equity (ttm) -18 %
Qtrly Rev. Growth 3.448e+007 %
Gross Profit (p.s.) -1.39
Sales Per Share -11.78
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -93 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -0.3
Price to Book value 0
Price to Sales -0.44
Price to Cash Flow 3.18
Stock Dividends
Dividend 0
Forward Dividend 9.39e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android